These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25540623)

  • 1. Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans.
    Lu Y; Griffen SC; Boulton DW; Leil TA
    Front Pharmacol; 2014; 5():274. PubMed ID: 25540623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
    Yakovleva T; Sokolov V; Chu L; Tang W; Greasley PJ; Peilot Sjögren H; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
    Diabetes Obes Metab; 2019 Dec; 21(12):2684-2693. PubMed ID: 31423699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.
    Rieg T; Masuda T; Gerasimova M; Mayoux E; Platt K; Powell DR; Thomson SC; Koepsell H; Vallon V
    Am J Physiol Renal Physiol; 2014 Jan; 306(2):F188-93. PubMed ID: 24226519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules.
    Mori K; Saito R; Nakamaru Y; Shimizu M; Yamazaki H
    Biopharm Drug Dispos; 2016 Nov; 37(8):491-506. PubMed ID: 27604638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
    Ohgaki R; Wei L; Yamada K; Hara T; Kuriyama C; Okuda S; Ueta K; Shiotani M; Nagamori S; Kanai Y
    J Pharmacol Exp Ther; 2016 Jul; 358(1):94-102. PubMed ID: 27189972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
    Mori-Anai K; Tashima Y; Nakada T; Nakamaru Y; Takahata T; Saito R
    Biopharm Drug Dispos; 2020 Nov; 41(8-9):352-366. PubMed ID: 33085977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
    Gallo LA; Wright EM; Vallon V
    Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice.
    Spatola L; Finazzi S; Angelini C; Dauriz M; Badalamenti S
    Diabetes Ther; 2018 Feb; 9(1):427-430. PubMed ID: 29177922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
    Girard J
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model.
    Demin O; Yakovleva T; Kolobkov D; Demin O
    Front Pharmacol; 2014; 5():218. PubMed ID: 25352807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved glycemic control in mice lacking Sglt1 and Sglt2.
    Powell DR; DaCosta CM; Gay J; Ding ZM; Smith M; Greer J; Doree D; Jeter-Jones S; Mseeh F; Rodriguez LA; Harris A; Buhring L; Platt KA; Vogel P; Brommage R; Shadoan MK; Sands AT; Zambrowicz B
    Am J Physiol Endocrinol Metab; 2013 Jan; 304(2):E117-30. PubMed ID: 23149623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
    Dominguez Rieg JA; Rieg T
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):43-52. PubMed ID: 31081587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule.
    Ghezzi C; Yu AS; Hirayama BA; Kepe V; Liu J; Scafoglio C; Powell DR; Huang SC; Satyamurthy N; Barrio JR; Wright EM
    J Am Soc Nephrol; 2017 Mar; 28(3):802-810. PubMed ID: 27620988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus.
    Takebayashi K; Inukai T
    J Clin Med Res; 2017 Sep; 9(9):745-753. PubMed ID: 28811850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2.
    Powell DR; Smith MG; Doree DD; Harris AL; Xiong WW; Mseeh F; Wilson A; Gopinathan S; Diaz D; Goodwin NC; Harrison B; Strobel E; Rawlins DB; Carson K; Zambrowicz B; Ding ZM
    Pharmacol Res Perspect; 2015 Mar; 3(2):e00129. PubMed ID: 26038705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane.
    Chichger H; Cleasby ME; Srai SK; Unwin RJ; Debnam ES; Marks J
    Exp Physiol; 2016 Jun; 101(6):731-42. PubMed ID: 27164183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
    Danne T; Biester T; Kordonouri O
    Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using a Mathematical Modeling To Simulate Pharmacokinetics and Urinary Glucose Excretion of Luseogliflozin and Explore the Role of SGLT1/2 in Renal Glucose Reabsorption.
    Wang Z; Wang G; Ren J
    ACS Omega; 2022 Dec; 7(51):48427-48437. PubMed ID: 36591124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach.
    Yamaguchi K; Kato M; Suzuki M; Hagita H; Takada M; Ayabe M; Aso Y; Ishigai M; Ikeda S
    J Pharmacol Exp Ther; 2013 Apr; 345(1):52-61. PubMed ID: 23386251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.